Prepare for the future of pharma with our report spotlighting the most anticipated late-stage drug launches expected in 2026. From first-in-class therapies to blockbuster contenders, this report delivers the insights you need to stay ahead in a rapidly evolving market.
Featured Launches Include:
- Takeda’s oveporexton – a first-in-class orexin-2 agonist for narcolepsy
- Amgen’s bemarituzumab – targeting FGFR2b in gastric cancer
- Novo Nordisk’s CagriSema – a dual GLP-1/amylin therapy for obesity
- Moderna’s mRNA-1083 – a pan-respiratory vaccine for COVID-19 & flu
- Orca Bio’s Orca-T – redefining transplant care in hematologic cancers
Download the report abstract today.
Enrich your strategic lens with real-time event tracking and analysis that delivers a full understanding of how major market movements and drug developments could impact the value of your assets.
Support the development and validation of your strategic commercial plans and ensure your commercial decisions are in line with marketplace realities. Datamonitor Healthcare delivers the latest insights and expert coverage of key disease areas, treatments, drugs, market access, and trends.
